Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Investing.com -- PMV Pharmaceuticals Inc (NASDAQ:PMVP) stock rose 2.2% on Friday after the company reported encouraging clinical trial results for its cancer drug rezatapopt, showing responses across multiple tumor types.
The precision oncology company presented updated data from the Phase 2 pivotal portion of its PYNNACLE clinical trial at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The trial evaluated rezatapopt in patients with advanced solid tumors harboring a specific genetic mutation called TP53 Y220C.
Results showed a 34% overall response rate among 103 evaluable patients across all cohorts, with a median duration of response of 7.6 months. Particularly notable was the 46% response rate observed in the ovarian cancer cohort, where the median duration of response reached 8.0 months.
The drug demonstrated efficacy across eight different tumor types, including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma. Treatment-related adverse events were mostly Grade 1-2, with the most common being nausea, fatigue, and certain blood test elevations.
"Patients with TP53 Y220C-mutated advanced solid tumors are in need of better treatment options, particularly those with platinum-resistant and refractory ovarian cancer. The rezatapopt data presented today demonstrate very encouraging clinical activity, reinforcing the potential for rezatapopt to target the underlying biology of these cancers and providing a potential shift in the current treatment paradigm," said Dr. Alison Schram, Medical Oncologist at Memorial Sloan Kettering Cancer Center and study investigator.
PMV Pharmaceuticals plans to submit a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.